The purpose of this document is to offer new strategic guidance on the operational response to isolation of vaccine-derived polioviruses type 2 (VDPV2) from any source in the period leading up to the global withdrawal of trivalent oral polio vaccine (tOPV), anticipated to occur in April 2016.